| abstract |
Compounds of squaric acid of formula (1) where R means H or A; R1, R1 'each means, independently of each other, H, A, Hal, CN, NO2, C (= O) A, CHO, CH (OH) A, NH2, NH (C = O) A, COOH, COOA , SO2NH2, CONH2 or CONA2; R2 means OH, OA, Hal, CF3, NO2 or SO2NH2; A means unbranched, or C1-10 branched alkyl, where 1-7 H atoms may be replaced by F; X is missing, or means CH2, CHA, CA2 or as shown in the compound of formula (2), Hal means F, Cl, Br or I; m means 0, 1 or 2; n means 1, 2, 3 or 4; where bis- (4-hydroxy-phenylamino) -cyclobut-3-en-1,2-dione is excepted, as well as its pharmaceutically usable derivatives, tautomers, salts, solvates and stereoisomers, including mixtures in all proportions, they are inhibitors of SGK and can be used for the treatment of diseases and ailments dependent on SGK such as diabetes, obesity, metabolic syndrome (dyslipidemia), systemic and pulmonary hypertonia, diseases of the cardiovascular system and nephropathies, in general for any type of fibrosis and inflammatory processes. Claim 1: Compounds of formula (1) wherein R means H or A; R1, R1 'each means, independently of each other, H, A, Hal, CN, NO2, C (= O) A, CHO, CH (OH) A, NH2, NH (C = O) A, COOH, COOA , SO2NH2, CONH2 or CONA2; R2 means OH, OA, Hal, CF3, NO2 or SO2NH2; A means unbranched, or C1-10 branched alkyl, where 1-7 H atoms may be replaced by F; X is missing, or means CH2, CHA, CA2 or as shown in the compound of formula (2), Hal means F, Cl, Br or I; m means 0, 1 or 2; n means 1, 2, 3 or 4; where bis- (4-hydroxy-phenylamino) -cyclobut-3-en-1,2-dione is excepted, as well as its pharmaceutically usable derivatives, tautomers, salts, solvates and stereoisomers, including mixtures in all proportions. |